|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma显示文摘 | Nicola Personeni Silvia Bozzarelli Tiziana Pressiani Lorenza Rimassa Maria Chiara Tronconi Francesco Sclafani Carlo Carnaghi Vittorio Pedicini Laura Giordano Armando Santoro | 2012 | Journal of Hepatology2012，，1： | 3 |
| 2 | Optimized management of advanced hepatocellular carcinoma:Four long-lasting responses to sorafenib显示文摘The therapeutic options for hepatocellular carcinoma (HCC) have been so far rather inadequate.Sorafenib has shown an overall survival benefit and has become the new standard of care for advanced HCC.Nevertheless,in clinical practice,some patients are discontinuing this drug because of side effects,and misinterpretation of radiographic response may contribute to this.We highlight the importance of prolonged sorafenib ad-ministration,even at reduced dose,and of qualitative and careful radiographic evaluation.We observed two partial and two complete responses,one histologically confirmed,with progression-free survival ranging from 12 to 62 mo.Three of the responses were achieved following substantial dose reductions,and a gradual change in lesion density preceded or paralleled tumor shrinkage,as seen by computed tomography.This report supports the feasibility of dose adjustments to allow prolonged administration of sorafenib,and highlights the need for new imaging criteria for a more appropriate characterization of response in HCC. | Giovanni Abbadessa Lorenza Rimassa Tiziana Pressiani Cynthia Carrillo-Infante Emanuele Cucchi Armando Santoro | 2011 | World Journal of Gastroenterology2011，17，19： | 2 |
| 3 | Targeted agents for second-line treatment of advanced hepatocellular carcinoma显示文摘Over the past ten years,sorafenib,a multikinase inhibitor,has been the standard of care for patients with unresectable hepatocellular carcinoma(HCC)and wellpreserved liver function.Recently,lenvatinib,a different multikinase inhibitor,was shown to be non-inferior to sorafenib,in terms of survival,while all other agents previously tested failed to prove non-inferiority(or superiority)when compared to sorafenib.Similarly,in the second-line setting,most investigational drugs failed to provide better survival outcomes than placebo.However,in the last 2 years three positive phase III trials have been published in this setting.The RESORCE trial,a phase III study evaluating regorafenib in HCC patients who experienced disease progression after first-line treatment with sorafenib,showed better outcomes with regorafenib compared to placebo.More recently,the phase III CELESTIAL trial demonstrated the superiority of cabozantinib,a multikinase inhibitor targeting vascular endothelial growth factor receptor,MET,and AXL,vs placebo in the second-and third-line setting in patients progressing on or intolerant to sorafenib.The survival benefits of a sustained anti-angiogenic inhibition were demonstrated also with ramucirumab in the phase III REACH-2 trial in patients previously treated with sorafenib and who had high baseline alpha-fetoprotein levels.Overall,the adverse events reported in these trials were in line with the known safety profiles of the tested agents.After nearly a decade of a certain degree of stagnation,we are now witnessing a period of novel therapeutic advances with multikinase inhibitors and monoclonal antibodies that will likely change the treatment scenario of HCC. | Nicola Personeni Tiziana Pressiani Silvia Bozzarelli Lorenza Rimassa | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 2 |
| 4 | Phase Ⅱ study of NGR-hTNF,a selective vascular targeting agent,in patients with metastatic colorectal cancer after failure of standard therapy显示文摘 | Santoro A Rimassa L Sobrero AF | 2010 | Eur J Cancer2010，46，15： | 1 |
| 5 | Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy显示文摘 | Carnaghi C Troneoni MC Rimassa L | 2007 | Nuclear medicine review Central & Eastern Europe2007，10，1： | 1 |
| 6 | Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma显示文摘Tumor biopsies may help to reliably distinguish hepatocellular carcinoma(HCC) from other tumors, mostly cholangiocarcinoma as well as to identify the patient populations who most benefit from target-driven HCC treatments, in order to improve the success rate of experimental therapies. Clarifying tumor biology may also lead to identify biomarkers with prognostic role and/or enabling to predict response or resistance to therapies. Recently, clinical trials have more efficiently included biomarker endpoints and increasingly collected tumor tissue from enrolled patients. Due to their frail status and sometimes fast-progressing disease, the performance status of patients with HCC progressing on first-line therapy can deteriorate quickly, preventing their enrollment in clinical trials. However, the challenge of identifying the proper patient at the proper time can be overcome by periodic inter-department meetings involving the key specialists taking care of HCC patients, and solid networks between research centers and referring institutions. An early planned biopsy would also facilitate timely inclusion of patients in biology-driven clinical trials. Ultimately, institution of multidisciplinary teams can optimize treatment choice, biopsy timing, and quick enrollment of patients in clinical trials, before their performance status deteriorates. | Lorenza Rimassa Maria Reig Giovanni Abbadessa Markus Peck-Radosavljevic William Harris Vittorina Zagonel Davide Pastorelli Elena Rota Caremoli Camillo Porta Nevena Damjanov Hitendra Patel Bruno Daniele Maria Lamar Brian Schwartz Terri Goldberg Armando Santoro Jordi Bruix | 2017 | World Journal of Gastroenterology2017，23，13： | 1 |
| 7 | Opportunities to Support the Widespread Adoption of Software Agent Technologies 显示文摘 | Calisti M Rimassa G | 2009 | International Journal of Agent-Oriented Software Engineering2009，3，4： | 1 |
| 8 | Tivantinib for second- line treatment of advanced hepatocellular carcinoma : randomised, placebo-controlled phase 2 study显示文摘 | Santoro A Rimassa L Borbath I | 2013 | Lancet Oncol2013，14，1： | 1 |
| 9 | Sorafenib therapy in advanced hepatocellular carcinoma:the SHARP trial显示文摘 | Rimassa L Santoro A | 2009 | Expert Rev Anticancer Ther2009，9，6： | 1 |
| 10 | The efficacy of hybrid chemotherapy with intravenous oxaliplatin and fo- linic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase 11 study 显示文摘 | Camaghi C Santoro A Rimassa L et a/ | 2007 | 1nvest New Drugs2007，25，5： | 1 |
| 11 | 5-Fluorouracil,dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors 显示文摘 | Rimassa L Carnaghi C | 1998 | Cancer1998，83，： | 1 |
| 12 | Developing multi-agent systems with a FIPA-compliant agent framework 显示文摘 | BELLIFEMINE F POGGI A RIMASSA G | 2001 | Software Practice & Experience2001，31，2： | 1 |
| 13 | An exploratory biomarkerstudy in metastatic tumors from colorectal cancer patients treatedwith bevacizumab显示文摘 | Sclafani F Rimassa L Colombo P | 2014 | Int J Biol Markers2014，10，： | 1 |
| 14 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma:A randomised,placebo-controlled phase 2 study显示文摘 | Santoro A Rimassa L Borbath I | 2013 | Lancet Oncol2013，14，1： | 1 |
| 15 | Irinotecan and raltitrexed: an active combination in advanced colorectal cancer显示文摘 | Carnaghi C Rimassa L Garassino I | 2002 | Ann Oncol2002，13，9： | 1 |
| 16 | Sorafenib in patientswith Child-Pugh class A and B advanced hepatocellular carcino-ma: a prospective feasibility analysis 显示文摘 | Pressiani T Boni C Rimassa L | 2013 | Annals of oncology2013，24，2： | 1 |
| 17 | Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial显示文摘 | Rimassa L Santoro A | 2009 | Expert Rev Anticancer Ther2009，9，6： | 1 |
| 18 | Developing multi-Agent systems with a FIPA-compliant Agent framework显示文摘 | BELLIFEMINE F POGGI A RIMASSA G | 2001 | Software Practice & Experience2001，31，2： | 1 |
| 19 | Developing multi-agent systems with a FIPA-compliant agent framework 显示文摘 | Bellifemine F Poggi A Rimassa G | 2001 | Software: Practice and Experience2001，31，2： | 1 |
| 20 | Clinical signficance of neuroendocrine phenotype in non-small cell lung cancer显示文摘 | Carnaghi C Rimassa L Garassino I | 2001 | Ann Oncol2001，12，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员